Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Stifel raised its price target on Artivion Inc. (NYSE:AORT) to $40.00 from $36.00 on Friday, maintaining a Buy rating following the company’s strong second-quarter performance. The medical device company, with a market capitalization of $1.88 billion, is trading near its 52-week high according to InvestingPro data.
The medical device company reported second-quarter revenues of $113 million, exceeding Stifel and consensus projections of approximately $108 million. Artivion achieved approximately 14% year-over-year organic revenue growth, driven significantly by its AMDS stent and stent-graft product in the United States. The company maintains strong financial health with a current ratio of 5.53, indicating robust liquidity.
The company’s aortic stent graft division growth accelerated to 22% year-over-year, up from 19% in the first quarter, indicating positive contribution from the AMDS product launched under humanitarian device exemption in December 2024.
Artivion’s On-X mechanical heart valve division delivered 24% year-over-year growth, with the company citing new account openings and increased utilization from existing customers as key drivers.
On the profitability front, Artivion reported second-quarter adjusted EBITDA of $24.8 million, representing approximately 33% year-over-year growth and surpassing Stifel and consensus projections of about $21 million, with the revenue outperformance being the primary contributor to the earnings beat. InvestingPro analysis reveals several additional insights about Artivion’s financial outlook, with analysts predicting the company will turn profitable this year. Get access to the full Pro Research Report and 10+ additional ProTips for comprehensive analysis.
In other recent news, Artivion Inc. reported strong financial results for the second quarter of 2025, with revenue reaching $113 million, marking a 14% year-over-year increase. This performance exceeded the consensus forecast of $108 million, as well as estimates from firms such as Canaccord Genuity and Oppenheimer. The company’s adjusted EBITDA came in at $24.8 million, surpassing both Canaccord’s projection of $23.7 million and the consensus estimate of $21.1 million. Artivion also achieved an earnings per share (EPS) of $0.24, significantly outperforming the anticipated loss of $0.0033.
Following these results, Needham raised its price target for Artivion to $45, maintaining a Buy rating, while Canaccord Genuity adjusted its target to $41, also with a Buy rating. Oppenheimer, meanwhile, set its price target at $40, maintaining an Outperform rating despite a slight reduction from a previous target of $42. Artivion has increased its revenue and EBITDA guidance for 2025, reflecting confidence in its growth trajectory. These developments highlight the company’s robust performance and favorable outlook, as noted by various analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.